Cargando…

Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics

Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and m...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenjie, Xie, Hongyu, Xia, Bairong, Zhang, Liuchao, Hou, Yan, Li, Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890305/
https://www.ncbi.nlm.nih.gov/pubmed/33613752
http://dx.doi.org/10.7150/jca.50733
_version_ 1783652487503282176
author Wang, Wenjie
Xie, Hongyu
Xia, Bairong
Zhang, Liuchao
Hou, Yan
Li, Kang
author_facet Wang, Wenjie
Xie, Hongyu
Xia, Bairong
Zhang, Liuchao
Hou, Yan
Li, Kang
author_sort Wang, Wenjie
collection PubMed
description Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and matched with 17 late stage, 23 benign ovarian tumor (BOT) and 24 uterine fibroid (UF) patients were utilized to perform plasma proteomics analysis using isobaric tag for relative and absolute quantitation (iTRAQ) method to identify differential diagnostic proteins of ovarian cancer patients. A validation set of 9 early stage, 11 late stage, 17 BOT and 16 UF collected by an independent cohort of samples with the same matching principles was examined to confirm the expressed levels of differential expression proteins by ELISA analysis. Results: CRP and ARHGEF 11 were identified as potential diagnostic biomarkers of ovarian cancer. Results of area under the curve (AUC) analysis suggested that combination of diagnostic proteins and CA125 achieved a much higher diagnostic accuracy compared with CA125 alone (AUC values: 0.98 versus 0.80), especially improved the specificity (0.97 versus 0.77). In addition, elevated plasma CRP levels were associated with increased risk of ovarian cancer. Conclusions: Current study found that plasma protein CRP was an indicator for monitoring the progression of ovarian cancer. Combination of plasma protein biomarkers with CA125 could be utilized to early diagnose of ovarian cancer patients.
format Online
Article
Text
id pubmed-7890305
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-78903052021-02-18 Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics Wang, Wenjie Xie, Hongyu Xia, Bairong Zhang, Liuchao Hou, Yan Li, Kang J Cancer Research Paper Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and matched with 17 late stage, 23 benign ovarian tumor (BOT) and 24 uterine fibroid (UF) patients were utilized to perform plasma proteomics analysis using isobaric tag for relative and absolute quantitation (iTRAQ) method to identify differential diagnostic proteins of ovarian cancer patients. A validation set of 9 early stage, 11 late stage, 17 BOT and 16 UF collected by an independent cohort of samples with the same matching principles was examined to confirm the expressed levels of differential expression proteins by ELISA analysis. Results: CRP and ARHGEF 11 were identified as potential diagnostic biomarkers of ovarian cancer. Results of area under the curve (AUC) analysis suggested that combination of diagnostic proteins and CA125 achieved a much higher diagnostic accuracy compared with CA125 alone (AUC values: 0.98 versus 0.80), especially improved the specificity (0.97 versus 0.77). In addition, elevated plasma CRP levels were associated with increased risk of ovarian cancer. Conclusions: Current study found that plasma protein CRP was an indicator for monitoring the progression of ovarian cancer. Combination of plasma protein biomarkers with CA125 could be utilized to early diagnose of ovarian cancer patients. Ivyspring International Publisher 2021-01-15 /pmc/articles/PMC7890305/ /pubmed/33613752 http://dx.doi.org/10.7150/jca.50733 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Wang, Wenjie
Xie, Hongyu
Xia, Bairong
Zhang, Liuchao
Hou, Yan
Li, Kang
Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title_full Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title_fullStr Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title_full_unstemmed Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title_short Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics
title_sort identifying potential markers for monitoring progression to ovarian cancer using plasma label-free proteomics
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890305/
https://www.ncbi.nlm.nih.gov/pubmed/33613752
http://dx.doi.org/10.7150/jca.50733
work_keys_str_mv AT wangwenjie identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics
AT xiehongyu identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics
AT xiabairong identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics
AT zhangliuchao identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics
AT houyan identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics
AT likang identifyingpotentialmarkersformonitoringprogressiontoovariancancerusingplasmalabelfreeproteomics